Ovid Therapeutics Inc Dossier - Source-backed chat

Ovid Therapeutics Inc

OVIDNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)0.50

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $2.43Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $474.6M

Enterprise Value $463.2M

Shares Outstanding 195.3M diluted

Next Earnings Date12 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Ovid Therapeutics is a clinical-stage biopharmaceutical company transitioning into a high-value neurology play, backed by a robust cash runway extending into 2029. The company's pipeline is anchored by two highly differentiated assets: OV329, a next-generation GABA-aminotransferase (GABA-AT) inhibitor with a superior safety profile compared to vigabatrin, and OV4071, a first-in-class oral KCC2 direct activator. With recent capital injections totaling over $113 million, Ovid is fully funded to reach multiple clinical proof-of-concept milestones, making it an attractive risk-reward opportunity at its current valuation.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets9 analysts · as of 18 Aug 2026

Low · most bearish analyst$4.00

Mean target$5.47

High · most bullish analyst$7.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$1.2015%

OV329 encounters unexpected safety signals or fails to show competitive efficacy in Phase 2 trials, limiting its commercial potential. Additionally, OV4071 fails to demonstrate clear pharmacodynamic effects in the ketamine challenge study, casting doubt on the viability of the oral KCC2 direct activator platform. Elevated R&D expenses accelerate cash burn, shortening the runway and forcing a dilutive capital raise at a depressed valuation.

Base CaseCentral scenario

$4.5060%

Ovid successfully initiates and advances its Phase 2 trials for OV329 in FOS and TSC, maintaining a clean safety profile. OV4071 completes Phase 1 healthy volunteer dosing with favorable tolerability and proceeds to proof-of-concept studies. The company's cash runway remains secure into 2029, allowing it to reach key clinical readouts without near-term dilutive financing, aligning the stock price with consensus analyst targets.

Bull CaseUpside scenario

$7.0025%

OV329 demonstrates robust seizure reduction in Phase 2 trials for focal onset seizures and tuberous sclerosis complex without the visual field constriction risks associated with older GABA-AT inhibitors. Concurrently, OV4071 establishes clear proof-of-mechanism in its ketamine challenge study, validating the KCC2 platform for neuropsychiatric indications like schizophrenia and Parkinson's disease psychosis. This dual-platform validation triggers significant upfront licensing deals, driving the stock toward the high-end analyst target.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Strong balance sheet with $165.6 million in cash, cash equivalents, and marketable securities as of March 31, 2026, extending the operational runway into 2029.
OV329 offers a validated mechanism of action (GABA-AT inhibition) with a significantly improved safety profile, potentially avoiding the severe ocular toxicities of vigabatrin.
First-in-class potential for the KCC2 direct activator platform (OV4071), targeting massive unmet needs in epilepsy, schizophrenia, and neurodegenerative psychoses.

Key Investment Risks

Clinical development risk inherent to early-stage CNS candidates, where historical failure rates are high.
Dependence on successful clinical readouts to sustain investor confidence and support future valuation inflection.
Potential for intense competition in the epilepsy and neuropsychiatry spaces from both established biopharma and emerging biotech players.

Thesis Invalidation Triggers

Failure of OV329 to demonstrate efficacy or acceptable safety in the upcoming Phase 2 clinical trials.
Inability of OV4071 to show proof-of-mechanism or direct KCC2 activation in the H2 2026 ketamine challenge study.
A significant acceleration in cash burn rate that reduces the projected runway to less than 18 months.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.